627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster III

An open label Phase 2 study of dapolsertib MEN1703 SEL24 as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B cell non Hodgkin lymphoma

Zilovertamab vedotin plus R CHP versus polatuzumab vedotin plus R CHP as first line therapy in participants with germinal center B cell diffuse large B cell lymphoma DLBCL The randomized open label Phase 2 waveline 011 Study

Zilovertamab vedotin plus R CHP versus R CHOP for first line treatment of diffuse large B cell lymphoma The phase 3 waveline 010 study

Polatuzumab vedotin combined with orelabrutinib and rituximab PRO Regimen as frontline therapy in elderly and frail patients with diffuse large B cell lymphoma DLBCL Results from A phase II study

Mitoxantrone hydrochloride liposome Lipo MIT combined with rituximab gemcitabine dexamethasone and cisplatin R GDPM in Relapsed Refractory diffuse large B cell lymphoma A multicenter single arm study

Efficacy and safety of rituximab high dose methotrexate and thiotepa R MT as first line induction therapy for primary central nervous system diffuse large B cell lymphoma

Intrathecal versus intravenous methotrexate in diffuse large B cell lymphoma A real world comparative outcomes study

Real world use of loncastuximab tesirine in heavily pretreated and high risk relapsed refractory large B cell lymphoma patients German multicenter analysis

Real world evidence of improved survival with pola based regimen in newly diagnosed DLBCL patients with extranodal involvement

Efficacy and safety of polatuzumab vedotin based regimens for elderly frail DLBCL patients A real world study

Comparing CHOP R CHOP R EPOCH and DA EPOCH R in HIV associated diffuse large B cell lymphoma A meta analysis and systematic review

Safety and effectiveness of brentuximab vedotin in patients with CD30 positive B cell lymphoma A multicenter prospective observational real world BRAVE study in China

Zanubrutinib combined with intrathecal chemotherapy for prevention of CNS relapse in high risk diffuse large B cell lymphoma

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients Results from the previd randomized trial by fondazione italiana linfomi FIL

Orelabrutinib combined with R CDOP regimen for first line treatment of diffuse large B cell lymphoma with high risk CNS IPI

Randomised Phase II study of acalabrutinib in combination with R CHOP treatment for diffuse large B cell lymphoma confirms safety and unimpaired treatment delivery

Ibrutinib in combination with rituximab methotrexate MTX vincristine and procarbazine R MPV i for newly diagnosed primary CNS lymphoma PCNSL